ONCrg Pipeline Strategies
reports provide comprehensive, cancer specific analyses of treatment landscapes for drugs in Ph I/II development and beyond. These resources include a presentation style PPT deck and a detailed PDF compendium which are refreshed quarterly to retain their accuracy and relevance.
Treatment Landscapes:
Each cancer area is described by the framework that best fits the specific cancer market, whether that is by patient subtype, molecular biomarkers, treatment stage and drug class and include visual analytics such as treatment algorithms, benchmarks, registrational trials, and key clinical criteria and guidelines to provide a big picture orientation of how new products may fit into the market landscape.
Product Profiles:
In each cancer area, products in Ph I/II development and beyond are evaluated by class and subclass, and summary slides are provided for each agent including clinical status by region, commercial rights, MOA/ROA, likely scenarios of use (patient subsets), SWOT analysis, milestones (upcoming and last) and clinical trial timelines.
Compendiums:
These cancer area reports take Product Profiles one step further by providing a comprehensive analysis and history of a drug's development and the details of clinical trials completed and in progress, including trial results when available.
Updates:
On a quarterly basis, ONCrg Pipeline Strategies reports are updated with relevant scientific, clinical and commercial developments. ONCrg disease area experts vigilantly monitor multiple secondary and primary sources including peer-reviewed literature, conference news, SEC filings, press releases, and electronic databases such as Adis R&D Insight, ClinicalTrials.gov.